A B S T R A C T Daily administration of estrogen antagonists to premenopausal women has been incorporated into the adjuvant treatment ofbreast cancer. We have studied the changes in reproductive hormones, pituitary responses to hypothalamic-releasing hormones, and endometrial histology during treatment with the antiestrogen tamoxifen in five healthy, premenopausal women. These studies were carried out during one menstrual cycle before and during two cycles ofantiestrogen treatment. All subjects continued to have regular menses with biphasic basal body temperature records. During treatment, estradiol (E2) levels were increased but followed the usual pattern reflecting follicular maturation and corpus luteum formation. The mean E2 concentration at the midcycle peak and during the luteal phase was twice that observed during the non-treatment cycle. By contrast, the concentrations and secretory patterns of luteinizing hormone and follicle-stimulating hormone were not greatly changed, and the gonadotropin responses to gonadotropin-releasing hormone were not suppressed.
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Endometrial biopsies obtained during the follicular phase of control and tamoxifen treatment cycles showed no differences whereas biopsies obtained during the luteal phase of tamoxifen cycles uniformly showed a lack of changes attributed to progesterone action with no progression of histologic changes beyond those expected on day [7] [8] of the luteal phase.
These observations are consistent with maturation of multiple ovarian follicles, a surprising finding considering the normal gonadotropin concentrations. The retarded development of the endometrium in the presence of supranormal serum E2 and progesterone concentrations is a morphologic demonstration of the antiprogestational effect of antiestrogens. The lack of gonadotropin suppression in the presence of hyper- INTRODUCTION Antiestrogens have recently been incorporated into the medical management of breast cancer for treatment of metastatic disease and in clinical trials of prophylactic adjuvant therapy (1, 2) . The hormonal responses to short courses of an estrogen antagonist used for ovulation induction have been described (3) . The endocrine consequences of daily antiestrogen therapy in women are largely unexplored. We considered that the effects of continuous antiestrogen therapy on hypothalamic-pituitary-ovarian regulation in premenopausal women might be especially profound with implications for both breast cancer treatment and normal physiology.
METHODS
Five healthy, paid volunteers, ages 28-43, were recruited from among employees of University Hospitals. All subjects gave a history of regular menses. To avoid any consequences for future fertility, women were chosen who were not desirous of additional pregnancies; two had had tubal ligations and the husbands of the other women had had vasectomies.
A 10-ml blood sample was obtained on alternate days for three consecutive menstrual cycles for determination of luteinizing hormone (LH),' follicle-stimulating hormone (FSH), estradiol (E2), and progesterone (P). In two subjects 12-h/overnight urine specimens were collected. After the first cycle, during which no treatment.was given, subjects received tamoxifen, 10 mg, twice daily, for two, and one subject for three consecutive cycles. Basal body temperatures were recorded daily throughout the study.
The subjects were admitted to the Clinical Research Center during the follicular phase of the first (nontreatment) cycle and again during the second cycle of tamoxifen therapy. On those occasions, 5-ml blood samples were obtained at 20-min intervals for 3 h followed by the simultaneous administration of 50 ug of gonadotropin-releasing hormone (GnRH) and 500 fi.g of thyrotropin-releasing hormone (TRH) to assess basal and stimulated concentrations of LH, FSH, thyroid-stimulating hormone (TSH), and prolactin (PRL). An Table II ). Fig. 4 shows that nearly all individual values during tamoxifen treatment were at or below the maximum value measured in individual subjects during the nontreatment cycle. Despite two to threefold increases in serum E2, FSH concentrations during the follicular phase of tamoxifen treatment cycles were not significantly different from control values (Table II, Figs. 1 and 4) , but during the luteal phase of tamoxifen cycles, mean FSH concentrations were significantly greater than the values during the nontreatment cycle, P < 0.001 (Table II) .
Serum PRL concentrations during tamoxifen cycles were not significantly different from nontreatment levels, nor were the PRL and TSH responses to TRH significantly different from those measured before antiestrogen treatment (Table II, Fig. 5 (11) . It followed that, like natural estrogens, nent and second tamoxifen antiestrogens underwent translocation from the cyto-:w the integrated hormone plasm to the nucleus. In contrast to 17,8-estradiol, the method of trapezoids. The antiestrogen-receptor complex exhibited long-term ts were done on days 9-12 nuclear retention, resulting in early estrogen-like rentrol cycle when serum E 1 ys -1 ohen tarmoEn sponses and later antagonism of estrogen action (12) . plasmic estrogen receptor (11), a postulate that is the subject of some controversy (13) . The cytoplasmic progesterone receptor has been demonstrated to be estrogen-dependent in the chick oviduct and other tissues including uterus, endometrium, dimethylbenzanthracene-induced mammary tumors, and human breast cells in tissue culture (14) (15) (16) (17) . Since tamoxifen can block the estrogen-induced increases in progesterone receptor (17, 18) , one might anticipate that antiestrogens would exhibit P antagonism as well.
The daily administration of tamoxifen to healthy women during the menstrual cycle resulted in the exaggerated secretion of E2 and P in a pattern consistent with normal but augmented follicular maturation. That this occurred in the absence of concomitant increases in gonadotropin secretion was the most striking and unexpected feature of this study. It differs from the effect of 5 d of treatment with clomiphene during the normal menstrual cycle which resulted in increased serum concentrations of both E2 and gonadotropins (19) . The mechanism responsible for hyperestrogenemia in the absence of increased gonadotropin concentrations is open to speculation. The concomitant increase in urinary estrogen and the sharp decrease in serum E2 after the midcycle peak suggests that the elevated serum levels reflect increased secretion rather than markedly altered metabolism. Other explanations for increased estrogen production include changes in estrogen and/or P action in the ovarian microenvironment, altered regulation of follicle atresia, or altered gonadotropin action as a consequence of changes in ovarian LH and FSH receptors.
The increased estrogen and P secretion during tamoxifen therapy could reflect enhanced gonadotropin stimulation of a single maturing follicle or could be the result of a simultaneous maturation of multiple follicles. Direct anatomic observations are needed to substantiate either of these alternatives. The presence of multiple preantral follicles resulting from diminished follicle atresia is one explanation for the apparent increase in gonadotropin action in the absence of increased gonadotropin concentrations. Ross and coworkers have shown that preantral follicle development is independent of gonadotropins, and is stimulatable by estrogens (20) (Table III) .
The P receptor concentration in human endometrium varies systematically during the menstrual cycle with maximum levels at midcycle (22) . This observation has been interpreted to indicate that the endometrial P receptor is estrogen dependent. Antiestrogen interference with estrogen-mediated synthesis of P receptor is the most attractive explanation for the observation of delayed endometrial maturation in women taking tamoxifen. These studies may provide the first morphologic demonstration of that effect in humans. Obviously, direct studies of receptor content are needed. One alternative explanation of this observation deserves comment. The administration of high doses of estrogens during the luteal phase results in reduced corpus luteum P secretion, suggesting a regulatory role for estrogen in the corpus luteum (23) (24) (25) . This has been proposed as a mechanism for the contraceptive effect of single, large doses of estrogen. Since estrogen administration results in diminished corpus luteum function, interference with estrogen action might result in increased P secretion.
Pituitary gonadotropin secretion is suppressed by E2 administration to either pre-or postmenopausal women, and most studies indicate that FSH is more sensitive to E2 feedback than LH (26, 27) . The two to threefold increase in serum E2 during tamoxifen treatment failed to suppress basal FSH or LH concentrations (Table II, Fig. 4 ), evidence for an antiestrogenic action of tamoxifen at the level of the hypothalamus or pituitary gland.
The enhanced gonadotropin responses to GnRH administered during tamoxifen treatment were not consistent with the effects of the drug on basal LH and FSH concentrations. Estrogens have been shown to either increase or decrease the gonadotropin response to GnRH depending on dose and duration of administration (28) (29) (30) . Other studies have shown the gonadotropin responses to GnRH were diminished by infusions of 17,8-estradiol that increased circulating E2 concentrations to levels comparable to those obtained during tamoxifen treatment (27, 29) . Likewise, chronic estrogen administration reduced or obliterated GnRH responsiveness (28) . By contrast, the hyperestrogenemia that accompanied tamoxifen therapy did not diminish the LH or FSH response to GnRH but rather appeared to prolong gonadotropin secretion (Fig. 6 ). This contrasts with the observation that clomiphene blocked the enhanced gonadotropin responses to GnRH that occur during those phases of the menstrual cycle characterized by higher circulating estrogen concentrations (30) . These disparate effects of tamoxifen on basal and GnRH-stimulated gonadotropin secretion are not readily explainable, but reinforce the impression that the actions of estrogen antagonists may vary among themselves and in different tissues.
Estrogen administration results in increased serum PRL concentrations and PRL responses to TRH are greater during the late follicular phase of the menstrual cycle, presumably related to higher circulating E2 levels (31, 32) . There was no significant change in basal or stimulated PRL secretion during tamoxifen administration (Table II, Fig. 5 ). Since serum E2 concentrations were 3 to 10-fold greater during tamoxifen administration, there was evidence for a predominant antiestrogen action on basal and stimulated PRL secretion.
These studies have raised important questions regarding the use of antiestrogens in the treatment of premenopausal breast cancer patients. Since estrogen administration to premenopausal women with breast cancer is generally avoided, it follows that there should be reluctance to intentionally increase serum E2 concentrations unless there was evidence that estrogen antagonism was predominant at the site of malignancy. There is as yet little information upon which to base that judgement. Clinically, antiestrogens have been used primarily in the treatment of metastatic disease in postmenopausal women. There are several reports of clinical responses in premenopausal women but no large, systematic studies (32) . There are no readily available methods for measurement of tamoxifen in blood and there is insufficient information from studies of tamoxifen inhibition of the growth of breast cancer cells in tissue culture to determine the critical antiestrogen/estrogen ratio. Whereas our studies in premenopausal women suggest that antiestrogen action might vary in different target tissues, there was evidence for estrogen antagonism at the hypothalamus and pituitary as well as the endometrium, providing some reason to belieye that an antiestrogen effect might also prevail at the level of the malignant cell.
